Roche Schizophrenia Drug And Clinical Trial Transparency

Published: Jan 23, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Roche announced today that its Phase 3 drug for schizophrenia, bitopertin, has failed two phase 3 studies. Bitopertin is being studied to determine if it can help schizophrenia patients with their “negative” symptoms such as lack of emotion and poor social skills. Unfortunately for Roche and schizophrenics, the first two studies that have been completed show that bitopertin is no different from placebo in improving negative symptoms after 24 weeks.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news